National Statistics
All data contained within this publication are National Statistics, with the exception of Breast Cancer Referrals data.
Published by: Information & Analysis
Directorate, Department of Health
Statisticians: Brian Reilly, Ben Simpson & Siobhán
Morgan
Contact: statistics@health-ni.gov.uk
Reporting Period: 1 January 2023 - 31 March
2023
Publication Date: 29 June 2023
Date of Next Publication: 28 September 2023
Coverage: Northern Ireland
Frequency: Quarterly
This statistical release presents information on waiting times for cancer services at hospitals in Northern Ireland and reports on the performance of Health and Social Care Trusts, against the draft waiting time targets for cancer care services which state that:
Information is detailed on the number of patients who began treatment by HSC Trust for all targets and by tumour site for the 31 and 62 day targets. All of the data contained in this release are published on the NISRA Data Portal and in CSV format to facilitate secondary analysis. These data are available at the following links:
https://data.nisra.gov.uk/product/HWTS
• In the quarter ending March 2023, 2,784 patients started their first definitive treatment, 1.6% (44) fewer than in the previous quarter (2,828), and 5.5% (146) more than in the same quarter last year (2,638).
• 87.8% (2,445) of those patients started treatment within 31 days of a decision to treat, compared with 89.3% (2,524) in the previous quarter and 86.2% (2,275) in the same quarter last year.
• In the quarter ending March 2023, 1,378 patients started treatment following an urgent GP referral for suspect cancer, 0.6% (9) fewer than in the previous quarter (1,387), and 9.5% (119) more than in the same quarter last year (1,259).
• 34.8% (479) of those patients started treatment within 62 days, compared with 36.5% (506) in the previous quarter and 41% (516) in the same quarter last year.
• In the quarter ending March 2023, there were 3,637 patients seen by a breast cancer specialist following an urgent referral for suspect breast cancer, 1.2% (46) fewer than in the previous quarter (3,683), and 5.7% (220) fewer than in the same quarter last year (3,857).
• 84.2% (3,062) of those referrals were seen within 14 days of their urgent referral for breast cancer, compared with 77.7% (2,863) in the previous quarter and 50.8% (1,958) in the same quarter last year.
• In the quarter ending March 2023, there were 6,690 new referrals for suspect breast cancer, of which 64.8% (4,337) were urgent.
Target: At least 98% of patients urgently referred with a suspected cancer should begin their first definitive treatment within 31 days of a decision to treat.
In the quarter ending March 2023, 2,784 patients started
treatment following a decision to treat, of which 87.8% (2,445) started
treatment within 31 days. The target was not achieved.
The number of patients starting treatment decreased by 1.6% (44) since last quarter, and increased by 5.5% (146) from the same quarter last year.
The percentage of patients starting treatment within 31 days decreased from 89.3% in the previous quarter and increased from 86.2% in the same quarter last year.
The Western HSC Trust had the highest proportion of patients starting treatment within 31 days (98.3%, 412 of 419 patients), while the Belfast HSC Trust had the lowest (83.5%, 973 of 1,165 patients).
Of tumour sites with more than 50 patients starting treatment during the quarter, Haematological Cancers had the highest percentage treated within 31 days (99.5%) while Skin Cancers had the lowest (77.7%).
Tumour Site | Total Treated | Change Since Last Quarter | % Within 31 Days | Change in % (pp) |
---|---|---|---|---|
Urological Cancer | 535 | 22 | 82.6% | -2.2 |
Skin Cancers | 449 | 12 | 77.7% | -4.9 |
Breast Cancer | 409 | -26 | 91.4% | -0.5 |
Lower Gastrointestinal Cancer | 329 | -14 | 94.5% | 3 |
Lung Cancer | 297 | -51 | 88.9% | -1.1 |
Upper Gastrointestinal Cancer | 239 | 16 | 93.7% | 0.9 |
Haematological Cancers | 205 | 39 | 99.5% | 0.1 |
Head/Neck Cancer | 139 | 17 | 88.5% | -5 |
Gynae Cancers | 115 | -39 | 80.9% | -2.9 |
Other | 30 | -21 | 90.0% | -8 |
Brain/Central Nervous System | 27 | -5 | 96.3% | -3.7 |
Sarcomas | 10 | 6 | 80.0% | -20 |
Target: At least 95% of patients urgently referred by a GP with suspected cancer should begin their first definitive treatment within 62 days.
During the quarter ending March 2023, 1,378 patients started treatment following an urgent GP referral for suspect cancer, of which 34.8% (479) started treatment within 62 days.
The number of patients treated decreased by 0.6% (9 patients) since last quarter, and increased by 9.5% (119 patients) since the same quarter last year.
The percentage of patients starting treatment within 62 days decreased from 36.5% in the previous quarter and decreased from 41% in the same quarter last year.
Note: Cases in which a patient was initially referred to one Trust for assessment and then subsequently transferred to another Trust for treatment are allocated 0.5 to each Trust.
The Southern HSC Trust reported the highest proportion of patients starting treatment within 62 days at 44.2% (97 of 219.5 patients). The lowest proportion was reported by the Belfast HSC Trust at 28.4% (118 of 415 patients).
Of tumour sites with more than 50 patients starting treatment during the quarter, Breast Cancer had the highest percentage treated within 62 days (87%) while Urological Cancer had the lowest (13.5%).
Tumour Site | Total Treated | Change Since Last Quarter | % Within 62 Days | Change in % (pp) |
---|---|---|---|---|
Urological Cancer | 363 | 2 | 13.5% | -6.7 |
Skin Cancers | 278 | 7 | 45.3% | 2.2 |
Breast Cancer | 184 | -19 | 87.0% | 5.2 |
Lower Gastrointestinal Cancer | 178 | 10 | 19.1% | -1.1 |
Upper Gastrointestinal Cancer | 100 | 22 | 28.0% | 2.4 |
Lung Cancer | 83 | -15 | 43.4% | 7.7 |
Gynae Cancers | 65 | -20 | 15.4% | -2.3 |
Head/Neck Cancer | 58 | -2 | 13.8% | -12.9 |
Haematological Cancers | 55 | 19 | 43.6% | -6.4 |
Other | 10 | -14 | 30.0% | -7.5 |
Brain/Central Nervous System | 2 | 1 | 0.0% | -100 |
Sarcomas | 2 | 0 | 50.0% | -50 |
Target: All urgent breast cancer referrals should be seen within 14 days.
During the quarter ending March 2023, 3,637 patients were seen by a breast cancer specialist following an urgent referral, of which 84.2% (3,062) were seen within 14 days.
The number of patients seen decreased by 1.2% (46 patients) from last quarter, and decreased by 5.7% (220 patients) from the same quarter last year.
The percentage of patients seen within 14 days increased from 77.7% in the previous quarter and increased from 50.8% in the same quarter last year.
During the quarter ending March 2023, the Belfast HSC Trust achieved the target of seeing all 685 urgent breast cancer referrals within 14 days.
During the quarter ending March 2023, 6,690 referrals were received by HSC Trusts for suspect breast cancer, of which 64.8% (4,337) were classified as urgent.
The number of patients referred and the proportion categorised as urgent has remained broadly steady since June 2016, with the exception of a reduction in the number of routine referrals during the quarter ending June 2020.
Data used to report on the 31 and 62 day targets are sourced from the Cancer Patient Pathway System (CaPPS), the data system used to administer cancer treatment services within Health and Social Care Trusts in Northern Ireland.
Data used to report on the breast cancer activity and referrals are sourced from the Patient Administration System, an administrative system used to manage, record and monitor hospital waiting lists within Health and Social Care Trusts in Northern Ireland. Hospital Information Branch introduced this methodology for the collection of breast cancer waiting time information in April 2017. Information was originally sourced from the Departmental SDR2 Return in aggregate format.
Regionally consistent data collection for cancer waiting times has been in place since April 2008. Cancer referrals data has been collected from April 2016.
All data presented in this publication have been validated and quality assured by Hospital Information Branch in conjunction with HSC Trusts.
The 31 day target relates to all patients who received a first definitive treatment for cancer during each of the three months covered in the publication, irrespective of their source or type of referral.
This is measured from the date on which the patient and the clinician agree the planned treatment and ends on the date the patient receives their first definitive treatment for cancer. Adjustments are made to the completed waiting time in the event of a patient cancelling or self-deferring treatment or because of suspension for either medical or social reasons.
The 62 day target relates to patients who received a first definitive treatment for cancer during each of the three months covered in the publication, following an urgent referral for suspect cancer from a General Practitioner or a routine GP referral that has subsequently been reclassified as urgent by a cancer specialist. Referrals from sources other than a GP, routine referrals and patients who have not been given an ICD 10 diagnosis are excluded.
This is measured from the date an initial urgent GP referral for suspect cancer is received by the HSC Trust and ends on the date the patient receives their first definitive treatment for cancer. Adjustments are made to the completed waiting time in the event of a patient cancelling or self-deferring treatment or because of suspension for either medical or social reasons.
Prior to June 2009, the target relating to waiting time for treatment following an urgent GP referral for suspect cancer was that at least 75% of patients urgently referred with a suspect cancer should begin their first definitive treatment within 62 days of referral.
Breast cancer activity reported against the 14 day target relates to all urgent referrals for suspect breast cancer that were first seen during each of the three months covered in the publication, irrespective of the source of referral. Figures include routine referrals that have subsequently been reclassified by a breast specialist as urgent and exclude urgent referrals reclassified as routine.
This is measured from the date an initial breast cancer referral is first received by the HSC Trust, and ends on the date that the patient attends their first outpatient appointment with a breast cancer specialist. Adjustments are made to the completed waiting time in the event of a patient cancelling, self-deferring or failing to attend a first outpatient appointment.
Figures provided in the Breast Cancer Referrals section reflect all new referrals received for suspect breast cancer irrespective of the source or urgency of referral. Referrals for breast cancer can be for advice, assessment or both.
The measurement of a patient’s waiting time against the 62 day target includes cases in which a patient was initially referred to one Trust for consultant assessment but was then subsequently transferred to another Trust for treatment. In such cases, the responsibility for that patient is shared, with 0.5 allocated to the Trust where the patient was first assessed and 0.5 to the Trust of first treatment. For example, if a patient is initially referred for assessment in the Southern HSC Trust and is then transferred to the Belfast HSC Trust where they receive treatment 70 days after their initial GP referral, both the Southern and Belfast HSC Trusts will report 0.5 of a patient treated who waited over 62 days.
For the 31 day target, all patients are reported against the Trust providing their treatment.
Breast cancer activity and referrals are all reported against the Trust the patient is referred to.
The 31 and 62 day targets relate to patients who received a first definitive treatment for cancer having been given an ‘International Classification of Diseases 10’ (ICD 10) diagnosis. Patients that have not been given an ICD 10 diagnosis are excluded.
Tumour sites are assigned by aggregation of applicable ICD 10 codes.
Data for all cancers are included except for basal cell carcinoma.
A breakdown of these statistics by Trust and tumour site is not routinely published. Due to the relatively small number of patients involved and disclosure control needed to preserve the privacy of individual patients, the inferences that could be drawn from the data at this level of breakdown are impacted.
These statistics include patients living outside Northern Ireland and privately funded patients seen in Health and Social Care hospitals in Northern Ireland.
Technical guidance and definitions, as well as notes on how to use the date contained within this statistical release are available at the following link:
https://www.health-ni.gov.uk/publications/cancer-waiting-times-guidance-and-returns
Data detailed in this publication are also available on the NISRA Data Portal and in CSV format to aid secondary analysis.
The Data Portal allows users to filter results, plot interactive charts and read data via API queries and to download data in CSV, XLSX, JSON-stat and PX formats. It can be accessed at the following link: https://data.nisra.gov.uk/product/HWTS
CSV files are available to download at the following link: https://www.health-ni.gov.uk/publications/northern-ireland-waiting-time-statistics-cancer-waiting-times-January-March-2023.
Statistics on waiting times for inpatients, outpatients, diagnostic services and emergency care are available at the following link: https://www.health-ni.gov.uk/topics/doh-statistics-and-research/hospital-waiting-times-statistics
The United Kingdom Statistics
Authority has designated these statistics as National Statistics, in
accordance with the Statistics and Registration Service Act 2007 and
signifying compliance with the Code of Practice for Statistics.
National Statistics status means that official statistics meet the
highest standards of trustworthiness, quality and public value.
It is the Department of Health’s responsibility to maintain
compliance with the standards expected of National Statistics. If we
become concerned about whether these statistics are still meeting the
appropriate standards, we will discuss any concerns with the Authority
promptly. National Statistics status can be removed at any point when
the highest standards are not maintained and reinstated when standards
are restored.
The statistics underwent a full assessment against the Code of
Practice in 2011. Designation was awarded in December 2013.
Since the assessment by the Office for Statistics Regulation, we have
continued to comply with the Code of Practice for Statistics.
Further information on the Code of Practice for Statistics is available at: https://code.statisticsauthority.gov.uk/
Please contact Hospital Information Branch for assistance with accessibility requirements or alternative formats. Email: statistics@health-ni.gov.uk
This publication is Crown copyright and may be reproduced free of charge in any format or medium. Any material used must be acknowledged, and the title of the publication specified.